by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | May 16, 2025 | Podcast
In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling...
by Scott Larrivee | May 12, 2025 | News
Radiopharmaceutical experts and researchers to gather June 19-20 in New Orleans NEW ORLEANS – May 12, 2025 – The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will...
by Scott Larrivee | Jan 16, 2025 | News
Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply VALENCIA, Calif. and GOTHENBURG, Sweden – Jan. 16, 2025 – Nusano, a...
by Scott Larrivee | Mar 20, 2024 | News
Presentation materials Download VALENCIA, Calif. – March 20, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt,...
